Role of LRRK2 kinase activity in the pathogenesis of Parkinson's disease

Biochemical Society Transactions

Volumn 40, Issue 5, 2012, Pages 1058-1062

  Greggio, Elisa ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Autophosphorylation; GTPase; Leucine rich repeat kinase 2 (LRRK2); Moesin; Parkinson's disease; Tau

Indexed keywords

ACTIN; ALPHA SYNUCLEIN; ALPHA TUBULIN; BETA TUBULIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EZRIN; FAS ANTIGEN; GUANOSINE TRIPHOSPHATASE; LEUCINE RICH REPEAT KINASE 2; MOESIN; RADIXIN;

AMINO TERMINAL SEQUENCE; AUTOPHOSPHORYLATION; BLOOD BRAIN BARRIER; CARBOXY TERMINAL SEQUENCE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; IC 50; IN VITRO STUDY; IN VIVO STUDY; MICROTUBULE; MISSENSE MUTATION; NEUROPATHOLOGY; OUTCOME ASSESSMENT; PARKINSON DISEASE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RECEIVER OPERATING CHARACTERISTIC; REVIEW; SIGNAL TRANSDUCTION;

HUMANS; MUTATION; PARKINSON DISEASE; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES;

EID: 84866648030     PISSN: 03005127     EISSN: 14708752     Source Type: Journal    
DOI: 10.1042/BST20120054     Document Type: Review

References (51)

1. Burbulla, L.F. and Kruger, R. (2011) Converging environmental and genetic pathways in the pathogenesis of Parkinson's disease. J. Neurol. Sci. 306, 1-8
2. Gasser, T., Hardy, J. and Mizuno, Y. (2011) Milestones in PD genetics. Mov. Disord. 26, 1042-1048
3. Funayama, M., Hasegawa, K., Kowa, H., Saito, M., Tsuji, S. and Obata, F. (2002) A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2-q13.1. Ann. Neurol. 51, 296-301
4. Paisan-Ruiz, C., Jain, S., Evans, E.W., Gilks, W.P., Simon, J., van der Brug, M., Lopez de Munain, A., Aparicio, S., Gil, A.M., Khan, N. et al. (2004) Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44, 595-600
5. Zimprich, A., Biskup, S., Leitner, P., Lichtner, P., Farrer, M., Lincoln, S., Kachergus, J., Hulihan, M., Uitti, R.J., Calne, D.B. et al. (2004) Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44, 601-607
6. Marin, I. (2006) The Parkinson disease gene LRRK2: evolutionary and structural insights. Mol. Biol. Evol. 23, 2423-2433
7. Greggio, E. and Cookson, M.R. (2009) Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions. ASN NEURO 1, art:e00002.doi:10.1042/AN20090007
8. Greggio, E. and Singleton, A. (2007) Kinase signaling pathways as potential targets in the treatment of Parkinson's disease. Exp. Rev. Proteomics 4, 783-792
9. Jaleel, M., Nichols, R.J., Deak, M., Campbell, D.G., Gillardon, F., Knebel, A. and Alessi, D.R. (2007) LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity. Biochem. J. 405, 307-317
10. Nichols, R.J., Dzamko, N., Hutti, J.E., Cantley, L.C., Deak, M., Moran, J., Bamborough, P., Reith, A.D. and Alessi, D.R. (2009) Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease. Biochem. J. 424, 47-60
11. Berger, Z., Smith, K.A. and Lavoie, M.J. (2010) Membrane localization of LRRK2 is associated with increased formation of the highly active LRRK2 dimer and changes in its phosphorylation. Biochemistry 49, 5511-5523
12. Greggio, E., Zambrano, I., Kaganovich, A., Beilina, A., Taymans, J.M., Daniels, V., Lewis, P., Jain, S., Ding, J., Syed, A. et al. (2008) The Parkinson disease-associated leucine-rich repeat kinase 2 (LRRK2) is a dimer that undergoes intramolecular autophosphorylation. J. Biol. Chem. 283, 16906-16914
13. Sen, S., Webber, P.J. and West, A.B. (2009) Dependence of leucine-rich repeat kinase 2 (LRRK2) kinase activity on dimerization. J. Biol. Chem. 284, 36346-36356
14. Anand, V.S., Reichling, L.J., Lipinski, K., Stochaj, W., Duan, W., Kelleher, K., Pungaliya, P., Brown, E.L., Reinhart, P.H., Somberg, R. et al. (2009) Investigation of leucine-rich repeat kinase 2: enzymological properties and novel assays. FEBS J. 276, 466-478
15. Gloeckner, C.J., Boldt, K., von Zweydorf, F., Helm, S., Wiesent, L., Sarioglu, H. and Ueffing, M. (2010) Phosphopeptide analysis reveals two discrete clusters of phosphorylation in the N-terminus and the Roc domain of the Parkinson-disease associated protein kinase LRRK2. J. Proteome Res. 9, 1738-1745
16. Greggio, E., Taymans, J.M., Zhen, E.Y., Ryder, J., Vancraenenbroeck, R., Beilina, A., Sun, P., Deng, J., Jaffe, H., Baekelandt, V. et al. (2009) The Parkinson's disease kinase LRRK2 autophosphorylates its GTPase domain at multiple sites. Biochem. Biophys. Res. Commun. 389, 449-454
17. Kamikawaji, S., Ito, G. and Iwatsubo, T. (2009) Identification of the autophosphorylation sites of LRRK2. Biochemistry 48, 10963-10975
18. Pungaliya, P.P., Bai, Y., Lipinski, K., Anand, V.S., Sen, S., Brown, E.L., Bates, B., Reinhart, P.H., West, A.B., Hirst, W.D. and Braithwaite, S.P. (2010) Identification and characterization of a leucine-rich repeat kinase 2 (LRRK2) consensus phosphorylation motif. PLoS ONE 5, e13672
19. Webber, P.J., Smith, A.D., Sen, S., Renfrow, M.B., Mobley, J.A. and West, A.B. (2011) Autophosphorylation in the leucine-rich repeat kinase 2 (LRRK2) GTPase domain modifies kinase and GTP-binding activities. J. Mol. Biol. 412, 94-110
20. Meylan, E. and Tschopp, J. (2005) The RIP kinases: crucial integrators of cellular stress. Trends Biochem. Sci. 30, 151-159
21. Hsu, C.H., Chan, D., Greggio, E., Saha, S., Guillily, M.D., Ferree, A., Raghavan, K., Shen, G.C., Segal, L., Ryu, H. et al. (2010) MKK6 binds and regulates expression of Parkinson's disease-related protein LRRK2. J. Neurochem. 112, 1593-1604
22. Hsu, C.H., Chan, D. and Wolozin, B. (2010) LRRK2 and the stress response: interaction with MKKs and JNK-interacting proteins. Neurodegener. Dis. 7, 68-75
23. Hynes, N.E. and Lane, H.A. (2005) ERBB receptors and cancer: the complexity of targeted inhibitors. Nat. Rev. Cancer 5, 341-354
24. Meixner, A., Boldt, K., Van Troys, M., Askenazi, M., Gloeckner, C.J., Bauer, M., Marto, J.A., Ampe, C., Kinkl, N. and Ueffing, M. (2011) A QUICK screen for Lrrk2 interaction partners: leucine-rich repeat kinase 2 is involved in actin cytoskeleton dynamics. Mol. Cell. Proteomics 10, M110.001172
25. Parisiadou, L., Xie, C., Cho, H.J., Lin, X., Gu, X.L., Long, C.X., Lobbestael, E., Baekelandt, V., Taymans, J.M., Sun, L. and Cai, H. (2009) Phosphorylation of ezrin/radixin/moesin proteins by LRRK2 promotes the rearrangement of actin cytoskeleton in neuronal morphogenesis. J. Neurosci. 29, 13971-13980
26. Gandhi, P.N., Wang, X., Zhu, X., Chen, S.G. and Wilson-Delfosse, A.L. (2008) The Roc domain of leucine-rich repeat kinase 2 is sufficient for interaction with microtubules. J. Neurosci. Res. 86, 1711-1720
27. Gillardon, F. (2009) Leucine-rich repeat kinase 2 phosphorylates brain tubulin-β isoforms and modulates microtubule stability: a point of convergence in parkinsonian neurodegeneration? J. Neurochem. 110, 1514-1522
28. Chan, D., Citro, A., Cordy, J.M., Shen, G.C. and Wolozin, B. (2011) Rac1 protein rescues neurite retraction caused by G2019S leucine-rich repeat kinase 2 (LRRK2). J. Biol. Chem. 286, 16140-16149
29. MacLeod, D., Dowman, J., Hammond, R., Leete, T., Inoue, K. and Abeliovich, A. (2006) The familial Parkinsonism gene LRRK2 regulates neurite process morphology. Neuron 52, 587-593
30. Ramonet, D., Daher, J.P., Lin, B.M., Stafa, K., Kim, J., Banerjee, R., Westerlund, M., Pletnikova, O., Glauser, L., Yang, L. et al. (2011) Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2. PLoS ONE 6, e18568
31. Winner, B., Melrose, H.L., Zhao, C., Hinkle, K.M., Yue, M., Kent, C., Braithwaite, A.T., Ogholikhan, S., Aigner, R., Winkler, J. et al. (2011) Adult neurogenesis and neurite outgrowth are impaired in LRRK2 G2019S mice. Neurobiol. Dis. 41, 706-716
32. Kawakami, F., Yabata, T., Ohta, E., Maekawa, T., Shimada, N., Suzuki, M., Maruyama, H., Ichikawa, T. and Obata, F. (2012) LRRK2 phosphorylates tubulin-associated tau but not the free molecule: LRRK2-mediated regulation of the tau-tubulin association and neurite outgrowth. PLoS ONE 7, e30834
33. Li, Y., Liu, W., Oo, T.F., Wang, L., Tang, Y., Jackson-Lewis, V., Zhou, C., Geghman, K., Bogdanov, M., Przedborski, S. et al. (2009) Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease. Nat. Neurosci. 12, 826-828
34. Qing, H., Wong, W., McGeer, E.G. and McGeer, P.L. (2009) Lrrk2 phosphorylates α synuclein at serine 129: Parkinson disease implications. Biochem. Biophys. Res. Commun. 387, 149-152
35. Imai, Y., Gehrke, S., Wang, H.Q., Takahashi, R., Hasegawa, K., Oota, E. and Lu, B. (2008) Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila. EMBO J. 27, 2432-2443
36. Kumar, A., Greggio, E., Beilina, A., Kaganovich, A., Chan, D., Taymans, J.M., Wolozin, B. and Cookson, M.R. (2010) The Parkinson's disease associated LRRK2 exhibits weaker in vitro phosphorylation of 4E-BP compared to autophosphorylation. PLoS ONE 5, e8730
37. Gloeckner, C.J., Schumacher, A., Boldt, K. and Ueffing, M. (2009) The Parkinson disease-associated protein kinase LRRK2 exhibits MAPKKK activity and phosphorylates MKK3/6 and MKK4/7, in vitro. J. Neurochem. 109, 959-968
38. Ho, C.C., Rideout, H.J., Ribe, E., Troy, C.M. and Dauer, W.T. (2009) The Parkinson disease protein leucine-rich repeat kinase 2 transduces death signals via Fas-associated protein with death domain and caspase-8 in a cellular model of neurodegeneration. J. Neurosci. 29, 1011-1016
39. Daniels, V., Vancraenenbroeck, R., Law, B.M., Greggio, E., Lobbestael, E., Gao, F., De Maeyer, M., Cookson, M.R., Harvey, K., Baekelandt, V. and Taymans, J.M. (2011) Insight into the mode of action of the LRRK2 Y1699C pathogenic mutant. J. Neurochem. 116, 304-315
40. Lewis, P.A., Greggio, E., Beilina, A., Jain, S., Baker, A. and Cookson, M.R. (2007) The R1441C mutation of LRRK2 disrupts GTP hydrolysis. Biochem. Biophys. Res. Commun. 357, 668-671
41. Liu, M., Kang, S., Ray, S., Jackson, J., Zaitsev, A.D., Gerber, S.A., Cuny, G.D. and Glicksman, M.A. (2011) Kinetic, mechanistic, and structural modeling studies of truncated wild-type leucine-rich repeat kinase 2 and the G2019S mutant. Biochemistry 50, 9399-9408
42. West, A.B., Moore, D.J., Choi, C., Andrabi, S.A., Li, X., Dikeman, D., Biskup, S., Zhang, Z., Lim, K.L., Dawson, V.L. and Dawson, T.M. (2007) Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum. Mol. Genet. 16, 223-232
43. Liu, M., Kang, S., Ray, S., Jackson, J., Zaitsev, A.D., Gerber, S.A., Cuny, G.D. and Glicksman, M.A. (2011) Kinetic, mechanistic, and structural modeling studies of truncated wild-type leucine-rich repeat kinase 2 and the G2019S mutant. Biochemistry 50, 9399-9408
44. Greggio, E., Jain, S., Kingsbury, A., Bandopadhyay, R., Lewis, P., Kaganovich, A., van der Brug, M.P., Beilina, A., Blackinton, J., Thomas, K.J. et al. (2006) Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol. Dis. 23, 329-341
45. Smith, W.W., Pei, Z., Jiang, H., Dawson, V.L., Dawson, T.M. and Ross, C.A. (2006) Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat. Neurosci. 9, 1231-1233
46. Lee, B.D., Shin, J.H., VanKampen, J., Petrucelli, L., West, A.B., Ko, H.S., Lee, Y.I., Maguire-Zeiss, K.A., Bowers, W.J., Federoff, H.J. et al. (2010) Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease. Nat. Med. 16, 998-1000
47. Zhang, J., Deng, X., Choi, H.G., Alessi, D.R. and Gray, N.S. (2012) Characterization of TAE684 as a potent LRRK2 kinase inhibitor. Bioorg. Med. Chem. Lett. 22, 1864-1869
48. Deng, X., Dzamko, N., Prescott, A., Davies, P., Liu, Q., Yang, Q., Lee, J.D., Patricelli, M.P., Nomanbhoy, T.K., Alessi, D.R. and Gray, N.S. (2011) Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2. Nat. Chem. Biol. 7, 203-205
49. Li, X., Patel, J.C., Wang, J., Avshalumov, M.V., Nicholson, C., Buxbaum, J.D., Elder, G.A., Rice, M.E. and Yue, Z. (2010) Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S. J. Neurosci. 30, 1788-1797
50. Tong, Y., Pisani, A., Martella, G., Karouani, M., Yamaguchi, H., Pothos, E.N. and Shen, J. (2009) R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice. Proc. Natl. Acad. Sci. U.S.A. 106, 14622-14627
51. Xiong, Y., Coombes, C.E., Kilaru, A., Li, X., Gitler, A.D., Bowers, W.J., Dawson, V.L., Dawson, T.M. and Moore, D.J. (2010) GTPase activity plays a key role in the pathobiology of LRRK2. PLoS Genet. 6, e1000902